Literature DB >> 175208

[Influence of somatastatin on oral glucose tolerance in autonomous hypersecretion of growth hormone, prolactin or insulin (author's transl)].

M Gottsmann, R Landgraf, W Londong, K Werder.   

Abstract

Oral glucose tolerance tests (OGTT) were performed for two subsequent days in 4 patients with active acromegaly, 2 patients with prolactin-producing pituitary adenomas and one insulinoma patient. Thirty minutes before the second OGTT 250 mug of somatostatin were injected intravenously as a bolus followed by a somatostatin infusion (500 mug) over 21/2 hours. The OGTTs were pathologic due to the hGH- and hPRL-induced insulin antagonism; they could not be normalized or improved by somatostatin. Only the peak of the blood sugar curve was shifted from one to two and a half hours after glucose administration; insulin and hGH levels were regularly suppressed after somatostatin whereas hPRL remained unchanged in most instances. Gastrin levels increased in all patients during the OGTT, the increase was suppressed in 4 patients. These findings show that the pathologic glucose tolerance due to insulin antagonism could not be improved by somatostatin in contrast to the deteriorated glucose tolerance in insulinopenic states.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 175208     DOI: 10.1007/bf01476456

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  22 in total

1.  [Somatostatin--effects and possible clinical significance].

Authors:  G Benker; D Reinwein
Journal:  Dtsch Med Wochenschr       Date:  1975-04-25       Impact factor: 0.628

2.  Effect of food on serum gastrin evaluated by radioimmunoassay.

Authors:  M G Korman; C Soveny; J Hansky
Journal:  Gut       Date:  1971-08       Impact factor: 23.059

3.  Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels.

Authors:  S S Yen; T M Siler; G W DeVane
Journal:  N Engl J Med       Date:  1974-04-25       Impact factor: 91.245

4.  Somatostatin: hypothalamic inhibitor of the endocrine pancreas.

Authors:  D J Koerker; W Ruch; E Chideckel; J Palmer; C J Goodner; J Ensinck; C C Gale
Journal:  Science       Date:  1974-04-26       Impact factor: 47.728

5.  Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients.

Authors:  C H Mortimer; W M Tunbridge; D Carr; L Yeomans; T Lind; D H Coy; S R Bloom; A Kastin; C N Mallinson; G M Besser; A V Schally; R Hall
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

6.  Inhibition of insulin secretion by somatostatin.

Authors:  K G Alberti; N J Christensen; S E Christensen; A P Hansen; J Iversen; K Lundbaek; K Seyer-Hansen; H Orskov
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

7.  [Morphology, clinical features, diagnosis, and treatment of Zollinger-Ellison syndrome (author's transl)].

Authors:  R Arnold; K Fuchs; R Siewert; H J Peiper; W Creutzfeldt
Journal:  Dtsch Med Wochenschr       Date:  1974-03-29       Impact factor: 0.628

8.  Acute suppression of insulin and glucose levels by synthetic somatostatin in normal human subjects.

Authors:  G W DeVane; T M Siler; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1974-05       Impact factor: 5.958

Review 9.  Carbohydrate homeostasis. I.

Authors:  R Levine; D E Haft
Journal:  N Engl J Med       Date:  1970-07-23       Impact factor: 91.245

10.  Studies on the pathogenesis of diabetes in acromegaly.

Authors:  R Luft; E Cerasi; C A Hamberger
Journal:  Acta Endocrinol (Copenh)       Date:  1967-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.